Purchase this article with an account.
A. Scheffer, J. F. Mineo, A. Bordron, C. A. Maurage, J. Trauet, M. Hé. Gevaert, J. P. Dessaint, M. Labalette, P. Labalette; Murine Model of Primary Ocular Lymphoma and Immunotherapy by Intravitreal Injection of Oligodeoxynucleotide. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1579. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Human primary intraocular lymphoma (PIOL) is a lethal disease with only few effective therapies available. However, there is currently no animal model of B-cell PIOL in immunocompetent host permitting the evaluation of new therapeutic approaches. The purpose of this study is to establish a new murine model of B-cell PIOL in an immunocompetent host and to evaluate an immunotherapy method based on intravitreal injection of oligodeoxynucleotide (ODN).
Lymphoma 38C13 B-cells were cultured in DMEM and then injected through the pars plana into the vitreous of immunocompetent C3H mice. Various amounts of these cells (ranging from 500 to 5000 cells per eye) were injected. ODN receptor (TLR9) expression was evaluated by an immunofluorescence method in eye and brain. ELISA tests were performed to compare two different ODN on their ability to induce cytokine secretion (IL-6 and TNF-α). Finally, the most effective (B type) was tested for its therapeutical effect by intravitreal injection.
Our murine model mimics human PIOL. Pathological examinations revealed that the tumor cells colonized the retina from the inner to the outer layers. TLR9 expression was visualized by immunofluorescence staining in the brain and the inner retinal layer. Intravitreal injection of ODN induced lymphocytic and macrophagic vitreous infiltration which abrogate retinal colonization.
We built a new murine model of B-cell PIOL in immunocompetent host that globally mimics human PIOL. In addition, we work out the bases of an immunotherapy method by intravitreal injection of ODN.
This PDF is available to Subscribers Only